Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Snehal Patel, the CEO and CFO of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), recently purchased 5,500 shares of the company’s common stock. The transaction, which took place on April 4, 2025, was executed at a price of $8.73 per share, totaling approximately $48,015. The purchase comes as the stock trades near its 52-week low of $8.29, with InvestingPro data showing the stock has declined about 49% over the past year. Following this acquisition, Patel now directly owns 5,558,002 shares of Greenwich LifeSciences. The purchase reflects Patel’s ongoing commitment to the company, where he also serves as a director and a ten percent owner. According to InvestingPro analysis, the stock currently appears oversold, with several additional technical indicators available to subscribers. The company maintains strong liquidity with a current ratio of 6.91, indicating robust short-term financial health.
In other recent news, Greenwich LifeSciences has reported significant progress in its Phase III clinical trial, FLAMINGO-01, which evaluates the immunotherapy GLSI-100 for preventing breast cancer recurrences. The company achieved its highest screening rate in the first quarter of 2025, exceeding 150 patients per quarter across 117 active sites in the US and EU, with plans to activate an additional 30 sites in the EU this year. The trial has also expanded into Germany, partnering with the German Breast Group to involve approximately 38 German sites. Recent safety data from the trial indicated no serious adverse events related to GLSI-100, leading the Data Safety Monitoring Board to recommend the continuation of the study without modifications. Preliminary data suggests that GLSI-100 is well-tolerated, aligning with Phase IIb results that showed a significant reduction in metastatic breast cancer recurrence rates. The trial includes a third open label arm for patients without the HLA-A02 allele, recently expanded to 250 patients following approvals by the FDA and EMA. The company is also analyzing open label HLA data, with findings supporting the sample size estimates for the trial and its interim analysis. Greenwich LifeSciences continues to focus on the development of GP2, aiming to replicate positive results from earlier trials and prepare for future commercialization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.